RANI Earnings — Rani Therapeutics Holdings, Inc. Class A Common Stock Post-ER Performance | BigEarnings
RANI — Rani Therapeutics Holdings, Inc. Class A Common Stock
XNAS · Healthcare · Biotechnology
Price$0.95
Market Cap$94.9M
P/E—
52W Range$0.39 – $3.87
Next Earnings2026-08-06
About Rani Therapeutics Holdings, Inc. Class A Common Stock
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
